Aditya Bagrodia

Yeah, I appreciate it. Thanks for kind of hammering the PSMA pet part. I feel like I maybe took that as a foregone conclusion, but it's important to specifically mention that. And I also think it's worth mentioning that if a PSMA pet is negative, that doesn't mean you shouldn't receive treatment necessarily.

Yeah, I appreciate it. Thanks for kind of hammering the PSMA pet part. I feel like I maybe took that as a foregone conclusion, but it's important to specifically mention that. And I also think it's worth mentioning that if a PSMA pet is negative, that doesn't mean you shouldn't receive treatment necessarily.

Yeah. It's always like a bit of a interesting thing when I read like a report or I hear that we're in a wait for the PSA rises a bit to get the PSMA pet. I'm like, right now we're just doing our due diligence, like box check. You don't have any obvious mess. Let's let's go. Okay, perfect, Todd.

Yeah. It's always like a bit of a interesting thing when I read like a report or I hear that we're in a wait for the PSA rises a bit to get the PSMA pet. I'm like, right now we're just doing our due diligence, like box check. You don't have any obvious mess. Let's let's go. Okay, perfect, Todd.

Yeah. It's always like a bit of a interesting thing when I read like a report or I hear that we're in a wait for the PSA rises a bit to get the PSMA pet. I'm like, right now we're just doing our due diligence, like box check. You don't have any obvious mess. Let's let's go. Okay, perfect, Todd.

And then maybe, you know, we kind of talked about some of the things that are coming to the pike that are going to allow us to personalize these intriguing, fascinating, complicated decisions, which are nearly certainly only to get more complicated, which is a good thing in the future.

And then maybe, you know, we kind of talked about some of the things that are coming to the pike that are going to allow us to personalize these intriguing, fascinating, complicated decisions, which are nearly certainly only to get more complicated, which is a good thing in the future.

And then maybe, you know, we kind of talked about some of the things that are coming to the pike that are going to allow us to personalize these intriguing, fascinating, complicated decisions, which are nearly certainly only to get more complicated, which is a good thing in the future.

What makes you excited about the future of management of patients with the biochemical recurrence after prostatectomy?

What makes you excited about the future of management of patients with the biochemical recurrence after prostatectomy?

What makes you excited about the future of management of patients with the biochemical recurrence after prostatectomy?

Yeah, I mean, it's things like they're moving at such an exciting and breakneck speed. And sometimes I think it's a little bit hard not to get super excited about the newest and the latest and the greatest. And, you know, one of the things that always strikes me with the Music Michigan group is how you all are thoughtful and the cart doesn't seem to get ahead of the horse very often.

Yeah, I mean, it's things like they're moving at such an exciting and breakneck speed. And sometimes I think it's a little bit hard not to get super excited about the newest and the latest and the greatest. And, you know, one of the things that always strikes me with the Music Michigan group is how you all are thoughtful and the cart doesn't seem to get ahead of the horse very often.

Yeah, I mean, it's things like they're moving at such an exciting and breakneck speed. And sometimes I think it's a little bit hard not to get super excited about the newest and the latest and the greatest. And, you know, one of the things that always strikes me with the Music Michigan group is how you all are thoughtful and the cart doesn't seem to get ahead of the horse very often.

You know, we've got the Indicate study, which I think is a great study, you know, in this exact clinical space over here, because I think we start doing things because it makes sense. It seems like that's where the data is heading.

You know, we've got the Indicate study, which I think is a great study, you know, in this exact clinical space over here, because I think we start doing things because it makes sense. It seems like that's where the data is heading.

You know, we've got the Indicate study, which I think is a great study, you know, in this exact clinical space over here, because I think we start doing things because it makes sense. It seems like that's where the data is heading.

And maybe even to the, you know, the folks out here that are interested, you know, some of these questions about how do we responsibly bring in new tests, new elements are still super ripe for research. And And with the higher grade stage cancer that we're treating, I think we're going to see more biochemical recurrence would be my sentiment.

And maybe even to the, you know, the folks out here that are interested, you know, some of these questions about how do we responsibly bring in new tests, new elements are still super ripe for research. And And with the higher grade stage cancer that we're treating, I think we're going to see more biochemical recurrence would be my sentiment.

And maybe even to the, you know, the folks out here that are interested, you know, some of these questions about how do we responsibly bring in new tests, new elements are still super ripe for research. And And with the higher grade stage cancer that we're treating, I think we're going to see more biochemical recurrence would be my sentiment.